A First-In-Human Phase 1 Trial of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

Written By Lara Wilson

Powderly, J., M.D. et al. The American Association for Cancer Research (AACR) Annual Meeting 2022. April 8–13, 2022

Lara Wilson
Previous

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells
Next

IO-108, a Fully Human Therapeutic Antibody Blocking the Myeloid Checkpoint LILRB2/ILT4, Promotes Innate and Adaptive Anti-Cancer Immunity in Preclinical Studies